Results 71 to 80 of about 6,850 (200)

Case Report: Recurrent Guillain–Barré Syndrome in a 56‐Year‐Old Male

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Recurrent Guillain–Barré syndrome (GBS) is an uncommon variant of immune‐mediated polyradiculoneuropathy. We report a 56‐year‐old male who had two distinct episodes of acute inflammatory demyelinating neuropathy within the span of 3 months. The first episode presented with an episode of ascending paralysis and areflexia, with nerve conduction ...
Farah Sadiq, Shayan Nawaz, Moeez Ahmad Saeed, Fahad Bilal, Hafiza Manahil Majeed, Wasfa Shafiq, Kashaf Imtiaz, Muhammad Husnain Ahmad, Ali Gohar   +8 more
wiley   +1 more source

The evaluation of approaches to the treatment of myasthenia gravis.

Medičnì Perspektivi, 2019
Myasthenia gravis is a relatively rare autoimmune disease with an undetermined aetiology which affects neuromuscular junctions. Currently, the following approaches to the treatment of myasthenia gravis are mainly distinguished: symptomatic treatment with
O. I. Kalbus, N. P. Shastun, S. O. Makarov, Yu. V. Bukreyeva, O. V. Somilo   +4 more
doaj   +1 more source

Pembrolizumab‐Induced Myositis: Diagnostic and Therapeutic Challenges From Two Case Reports and a Narrative Review

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Pembrolizumab, an anti‐PD‐1 immune checkpoint inhibitor, has transformed the treatment of multiple solid tumors. However, it can rarely cause immune‐related myositis, which may involve limb, bulbar, and respiratory muscles, posing a risk of severe morbidity and mortality. Early recognition and management are essential. We report two
Francesca Rifaldi, Niccolò Leandro Alessio, Francesca Caspani, Elena Bolzacchini, Monica Giordano, Paolo Pedrazzoli   +5 more
wiley   +1 more source

Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Tacrolimus monotherapy yields high remission in adult‐onset MG, especially in new‐onset or younger patients. Relapse is linked to low tacrolimus concentration and rapid tapering. Hyperglycemia was the most common ADR. Long‐term use may increase cancer risk.
Zhangyan Geng, Yuting Jiang, Nairong Xie, Wenjia Zhu, Hai Chen, Yaye Wang, Haoran Liu, Qinyao Liu, Congwen Lv, Yu Qian, Yan Lu, Li Di, Min Wang, Min Xu, Xinmei Wen, Bingchuan Xie, Yuwei Da   +16 more
wiley   +1 more source

The Anti-Acetylcholine Receptor Antibody Test in Suspected Ocular Myasthenia Gravis

Journal of Ophthalmology, 2014
Aim. To estimate the clinical significance of anti-acetylcholine receptor antibody (anti-AChR-Ab) levels in suspected ocular myasthenia gravis. Methods. In total, 144 patients complaining of fluctuating diplopia and ptosis were evaluated for serum levels
Jung Jin Lee, Kyung Min Koh, Ungsoo Samuel Kim   +2 more
doaj   +1 more source

Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody‐Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
In this exploratory study, no statistically significant differences in effectiveness, safety, or cost were observed between EFG and LPE, nor between RACT and oral immunosuppressants for pre‐thymectomy preparation in MG. These findings are hypothesis‐generating and warrant prospective validation.
Qian Zhou, Ting He, Yuanda Cheng, Kangzhi Chen, Yuzhen Ouyang, Xiaohua Dong, Guanzhong Shi, Zeyi Wen, Huan Yang   +8 more
wiley   +1 more source

Frontalis sling procedure for ocular myasthenia gravis

Clinical Ophthalmology, 2012
Shinichi Asamura1, Hirohiko Kakizaki2, Mitsuhiro Enjyo1, Takahiro Hashimoto1, Noritaka Isogai11Department of Plastic and Reconstructive Surgery, Kinki University School of Medicine, Osakasayama, Osaka, Japan; 2Department of Ophthalmology, Aichi Medical ...
Isogai N, Hashimoto T, Enjyo M, Kakizaki H, Asamura S   +4 more
doaj  

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

Ocular Myasthenia Gravis and Thymus Gland Hyperplasia–A Case Report

TNOA Journal of Ophthalmic Science and Research
Myasthenia gravis (MG) is caused by antibodies directed at acetylcholine receptors or functionally related proteins in the postsynaptic membrane at the neuromuscular junction.
Sujit Das
doaj   +1 more source

Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis

Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with AngioDynamics SmartPort (BP + AD).
Mugtaba Swar‐Eldahab, Barnabas Obeng‐Gyasi, Paul Haste, Matthew Krosin   +3 more
wiley   +1 more source